Literature DB >> 34775881

Managing the gastrointestinal side effects of GLP-1 receptor agonists in obesity: recommendations for clinical practice.

Sean Wharton1, Melanie Davies2,3, Dror Dicker4, Ildiko Lingvay5, Ofri Mosenzon6, Domenica M Rubino7, Sue D Pedersen8.   

Abstract

Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are well established in clinical practice for the treatment of type 2 diabetes, and are approved and recommended for weight management in overweight or obesity. Gastrointestinal side effects are well known as the most common adverse effects of these agents and represent a potential barrier for use, particularly at higher doses. Drawing on both published evidence and our collective clinical experience, we aim to guide practitioners through managing these side effects with a view to optimizing therapeutic outcomes with GLP-1RAs.

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 34775881     DOI： 10.1080/00325481.2021.2002616

Source DB:  PubMed          Journal:  Postgrad Med        ISSN： 0032-5481            Impact factor:   3.840


  5 in total

Review 1.  Comparisons of pleiotropic effects of SGLT2 inhibition and GLP-1 agonism on cardiac glucose intolerance in heart dysfunction.

Authors:  Belma Turan; Aysegul Durak; Yusuf Olgar; Erkan Tuncay
Journal:  Mol Cell Biochem       Date:  2022-05-22       Impact factor: 3.396

Review 2.  Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).

Authors:  Melanie J Davies; Vanita R Aroda; Billy S Collins; Robert A Gabbay; Jennifer Green; Nisa M Maruthur; Sylvia E Rosas; Stefano Del Prato; Chantal Mathieu; Geltrude Mingrone; Peter Rossing; Tsvetalina Tankova; Apostolos Tsapas; John B Buse
Journal:  Diabetologia       Date:  2022-09-24       Impact factor: 10.460

Review 3.  Glucagon-Like Peptide 1 Receptor Agonists: A Medication for Obesity Management.

Authors:  Mohamad B Taha; Tamer Yahya; Priyanka Satish; Rachel Laird; Arthur S Agatston; Miguel Cainzos-Achirica; Kershaw V Patel; Khurram Nasir
Journal:  Curr Atheroscler Rep       Date:  2022-05-28       Impact factor: 5.967

Review 4.  Preventing all-cause hospitalizations in type 2 diabetes with sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists: A narrative review and proposed clinical approach.

Authors:  Meir Schechter; Matan Fischer; Ofri Mosenzon
Journal:  Diabetes Obes Metab       Date:  2022-03-24       Impact factor: 6.408

Review 5.  How Far beyond Diabetes Can the Benefits of Glucagon-like Peptide-1 Receptor Agonists Go? A Review of the Evidence on Their Effects on Hepatocellular Carcinoma.

Authors:  Konstantinos Arvanitakis; Theocharis Koufakis; Kalliopi Kotsa; Georgios Germanidis
Journal:  Cancers (Basel)       Date:  2022-09-24       Impact factor: 6.575
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.